Distribution of Anti-Factor Xa Activity in Patients on Edoxaban Therapy for Non-Valvular Atrial Fibrillation

Background: The distribution of anti-factor Xa activity (AXA) values in non-valvular atrial fibrillation (NVAF) patients on edoxaban therapy has not been fully elucidated. Methods and Results: The steady-state trough and peak AXA values were measured in 66 NVAF patients. The trough AXA value did not differ significantly between the 60-mg and the 30-mg OD groups (0.17+/-0.13 IU/ml vs. 0.12+/-0.11 IU/ml, respectively; P=0.17). Similarly, the peak AXA value did not differ significantly between the 2 groups (1.45+/-0.81 IU/ml vs. 1.25+/-0.48 IU/ml, respectively; P=0.26). Conclusions: Recommended dosing should be followed for sufficient efficacy of edoxaban.